summary id# 5123 clinical study summary: study b9r- it...
TRANSCRIPT
-
CT Registry ID#5123 Page 1
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Summary ID# 5123
Clinical Study Summary: Study B9R- IT-GDFT
The Genetics and Neuroendocrinology in Children with GHD: A Part of GeNeSIS
Date summary approved by Lilly: 28 August 2006
Brief Summary of Results
This was a pilot study conducted in one European country in preparation of participation in an international more comprehensive study (GeNeSIS) for the characterization of genetic defects associated with hypopituitarism and the development of an accurate growth prediction model. The GeNeSIS study analysis at the 2004 datalock incorporates data belonging to this study.
Title of Study: The Genetics and Neuroendocrinology in children with GHD: A part of GeNeSIS Investigator(s): This multicenter study included 19 principal investigators. Study Center(s): This study was conducted at 19 study centers in 1 country. Length of Study: 1 year Date of first subject visit: 12 September 2001 Date of last subject visit: 01 September 2003
Phase of Development: 4
Objectives: Primary objectives:
• To characterize gene defects associated with hypopituitarism, growth disorder or short stature. [DNA analysis study]
• To develop accurate growth prediction models using clinical data (auxologic parameters, bone age) and biochemical data (insulin-like growth factor-I [IGF-I] and insulin-like growth factor binding protein-3 [IGFBP-3], urinary bone markers) [Growth prediction study].
Secondary Objectives: To collect any adverse event, whether or not considered drug-related
-
CT Registry ID#5123 Page 2
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Study Design: open-label, multicenter, national study. It was a part of GeNeSIS - The Genetics and Neuroendocrinology of Short Stature International Study - which is an open-label, multicenter, multinational, observational study, established as a post-marketing research program. It collects information on the clinical management of patients with short-stature, growth disorder or disorders of hypothalamic-pituitary function according to standard pediatric endocrinology practice, as documented by the attending endocrinologist. DNA Analysis Study: Patients, who fulfilled inclusion criteria, were eligible to enter B9R-IT-GDFT, in the DNA analysis study. Once a patient was enrolled in this study, a blood sample for genetic analysis was taken at baseline and sent to the central lab for analysis.
Growth Prediction Study: Patients who meet inclusion criteria and who have not yet received any growth hormone (GH) therapy were eligible to participate in the growth prediction study. Once a patient was
enrolled in this study, a blood sample for evaluation of IGFs was taken at baseline. After one month of GH
therapy a sample of urine for bone markers evaluation was also taken and sent to the central lab for
analysis.
Discussion of Design and Control This was an open-label, multicenter, national study for a total treatment period of 12 months (52 weeks) involving about 60 GHD pre-pubertal patients who at enrolment received Humatrope therapy administered from Visit 1 at the currently approved dosage for pediatric GHD (0.025-0.035 mg/Kg/day). All subjects, regardless of which study they were enrolled in (DNA and Growth prediction), underwent baseline anthropometric measurements and collection of blood sample for measurement of IGF-I, IGF-BP3 and blood chemistry and hematology for safety (if not available previously). At Visit 1, after giving informed consent, physical examination of patients to determine the diagnosis was performed according to the Schedule of Events, and blood sample was collected for thyroid function test (performed in a Local Laboratory), DNA analysis (only subjects enrolled in this study) (a central laboratory), IGF-I and IGF-BP3 (a central laboratory). A hand-wrist x-ray was performed to determine bone age. In addition, the subjects enrolled in Growth Prediction Study were given a urine collection kit and instructions to collect urine at home approximately 1 month after the start of somatropin therapy. One month (+ 1 week) after Visit 1, an interim history was collected including any adverse event, clinical evaluation, Humatrope® therapy information. At this visit, the patient brought his/her 24 hour urine collection for central laboratory to determine deoxypiridinoline crosslinks, galactosylhydroxylysine and glucosylgalctosylhydroxylysine. At Visit 2, after 3 months (+ 3 weeks) of GH treatment, an interim history was collected including any adverse event, clinical evaluation, Humatrope® therapy information. At Visit 3, after 6 months (+ 4 weeks), a blood sample was collected for IGF-I, IGF-BP3 performed in a different Central Lab. Clinical evaluation including any adverse event and Humatrope® therapy information was collected. At Visit 4, after 12 months (+ 4 weeks), a blood sample was collected for IGF-I, IGF-BP3 performed in a different Central Lab. A hand-wrist x-ray was performed to determine bone age. Clinical evaluation including any adverse event and Humatrope® therapy information was collected. Number of Subjects: Planned: 60. Entered: 36. Completed: 32.
-
CT Registry ID#5123 Page 3
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Main Criteria for Inclusion DNA Analysis Study:
• Fulfillment of criteria defined in the scoring system • They have never received any growth hormone therapy • GHD defined as:
- peak response of GH under any pharmacological stimulation
-
CT Registry ID#5123 Page 4
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Variables: Safety:
• Date of birth, sex, visit date • Diagnosis • Specific medical conditions, significant historical diagnoses, growth promoting
medications prior to study entry • Medications • Pre-existing conditions (data collected on “Pre-existing Conditions and Adverse Events”
running record) • Humatrope therapy: dose at entry into the study (dose per injection, unit, number of
injections per week), date of first dose of growth hormone after entry into the study • Adverse events
The frequency and percentage of adverse events for patients receiving Humatrope therapy were summarized in multiple ways including by body system and by underlying disorders. Serious adverse events were listed in detail for each individual patient. Detailed summaries of neoplastic disease recurrence were also presented. Efficacy: The following efficacy issues were explored: height and annualized height velocity. The participating physicians were contacted if the following data are not provided:
• Date of birth, sex, visit date • Diagnosis • GH testing results • Measurements (length or height) • Humatrope therapy (for Humatrope-treated patients): prescribed dose at entry into the
study (dose per injection, unit, number of injections per week) • Patients who, at the end of B9R-IT-GDFT, will be entered into GeNeSIS, will be
followed-up to the final height attainment (when their height velocity has dropped below 2 cm/year)
Gene defects: The following efficacy issues were explored: height and annualized height velocity. The participating physicians were contacted if the following data are not provided:
• Date of birth, sex, visit date • Diagnosis • GH testing results • Measurements (length or height) • Humatrope therapy (for Humatrope-treated patients): prescribed dose at entry into the
study (dose per injection, unit, number of injections per week) • Patients who, at the end of B9R-IT-GDFT, will be entered into GeNeSIS, will be
followed-up to the final height attainment (when their height velocity has dropped below 2 cm/year)
Bioanalytical: Not applicable Pharmacokinetic/Pharmacodynamic: Not applicable Health Outcomes: Not applicable Evaluation Methods: Statistical: Patients entered in the study were included in any given analysis only if they have the necessary data available for the analysis in question. Student’s t-test was used for the comparison of means from two variables when more variables or unpaired test were performed. Analysis of variance (ANOVA) was used. Growth Prediction was performed after 3 months of treatment as follows: baseline data (height, weight, bone age, pubertal stage, IGF-1 and IGFBP-3), urinary bone turnover markers (deoxypiridinoline crosslinks, galactosylhydroxylysine and glucosylgalctosylhydroxylysine) after 4 weeks, and height, IGF-1 and IGFBP-3 after 3 months were collected and was calculated using a mathematical algorhytm. The results were expressed as 1st year height velocity (HV) using the formulae 1-year HV(cm)=3.543-(2.337xBA)-(0.010xIGF-I)+(0.100xDPD)+(0.299x3month HV).
-
CT Registry ID#5123 Page 5
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Results:
The last patient was entered into treatment on 31 July 2002, instead of the planned date of 30 September 2001 because of the very low rate of enrollment of patients.
Patient Demographics
Completers’ demographics at baseline are summarized in Table 1.
-
CT Registry ID#5123 Page 6
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 1. Summary of Baseline Patient Demographics
-ANOVA p-values-
Group N Mean SD Median Q1 Q3 Min Max Raw Ranked
Age at diagnosis
All 32 5.09 3.73 4.73 1.90 7.57 0.03 14.67 0.775 0.727
Female 11 4.82 3.77 4.54 1.83 6.85 0.03 12.19
Male 21 5.23 3.79 4.92 2.00 7.67 0.06 14.67
Baseline bone age GP SDS (BAGP-CA)/SD
All 27 -3.73 1.19 -3.61 -4.36 -2.80 -6.41 -1.63 0.516 0.482
Female 9 -3.51 1.38 -3.41 -4.26 -2.42 -5.71 -1.63
Male 18 -3.84 1.11 -3.66 -4.36 -3.04 -6.41 -2.46
Baseline bone age GP delay (BAGP-CA)
All 31 -2.31 1.06 -2.34 -2.89 -1.42 -4.63 -0.54 0.523 0.395
Female 11 -2.14 1.22 -1.65 -3.51 -1.05 -4.26 -0.86
Male 20 -2.40 0.98 -2.41 -2.86 -1.92 -4.63 -0.54
Baseline bone age Greulich-Pyle
All 31 3.12 2.88 2.72 0.85 4.41 -0.47 10.37 0.790 0.717
Female 11 2.93 2.92 2.03 0.85 3.91 -0.14 9.73
Male 20 3.22 2.93 2.91 1.07 4.90 -0.47 10.37
Baseline relative bone age GP (BAGP/CA)
All 31 0.42 0.37 0.52 0.34 0.67 -1.00 0.80 0.783 0.840
Female 11 0.44 0.31 0.55 0.27 0.62 -0.16 0.80
Male 20 0.40 0.40 0.47 0.35 0.68 -1.00 0.75
baseline age (yrs)
All 32 5.28 3.60 4.84 2.18 7.61 0.47 14.72 0.811 0.862
Female 11 5.07 3.61 4.63 2.21 7.02 0.82 12.21
Male 21 5.39 3.68 5.06 2.14 7.75 0.47 14.72
Group N Mean SD Median Q1 Q3 Min Max Raw Ranked
-
CT Registry ID#5123 Page 7
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 1. Summary of Baseline Patient Demographics (concluded)
Target height (cm)
All 32 165.50 8.32 167.33 158.38 171.25 149.65 181.50
-
CT Registry ID#5123 Page 8
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 2. Disease Characteristics of Protocol Completers (N=32)
Diagnosis No (%) Level 1 GHD
Level 2
Number of patients (%)
32 (100.0) Idiopathic
Organic 23 (71.9) 9 (28.1)
Level 3 Classic Congenital
Level 4 UNK Abnormal pituitary development UNK
Number of patients (%) 23 (100) 23 (100) 8 (88.9)
1 (11.1)
Level 4 Abnormal pituitary development UNK
Level 5 Ectopic posterior pituitary Pituitary aplasia/absence Pituitary hypoplasia UNK
Number of patients (%)
8 (100) 4 (50) 1 (12.5) 3 (37.5) 24 (100)
The number of years on GH Treatment for all GHD patients is reported in Table 3.
Table 3. Total Years on GH Therapy
Years Number of Patients (%) 0 - 1 17 (53.1) > 1-2 15 (46.9) All 32 (100)
-
CT Registry ID#5123 Page 9
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Tanner Stage values at baseline and endpoint are presented in Table 4.
Table 4. Tanner Stages at Baseline and Endpoint
Tanner Stage at Baseline Females n (%) Males n (%) B1 11 (100) G1 19 (95) G2 1 (5) Tanner Stage at Last Visit Females n (%) Males n (%) B1 9 (81.8) G1 16 (80) B2 2 (18.2) G2 1 (5) Unknown 3 (15)
Abbreviations: B = breast; G = gonad; n = number of patients.
Efficacy Measures Growth Prediction Model Results: For the females an HV of 12.98± 4.82 cm/year was predicted after three months of observation and at the first year the HV was 13.05±3.91 cm/year; for the males an HV of 13.95±5.39 cm/year was predicted and at the first year the HV was 12.93±5.02 cm/year.
Height, height SDS, weight, weight SDS IGF-I SDS, IGF-I/IGFB-3 ratio, statisticall increased in all treatment groups and by age because pts. were going according with pts. enrolled characteristics .
In the same manner, IGFB-3 SDS was statistically increased during the study in males and total population (p
-
CT Registry ID#5123 Page 10
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
All results are summarized in the following pages (Table 5- Table 15):
Table 5. Summary of Height Velocity (cm/year)
SUMMARY OF HEIGHT VELOCITY SDS -ANOVA p-values-
Group N Mean SD Median Q1 Q3 Min Max Raw Ranked
Baseline height velocity
All 15 7.20 6.55 4.62 3.55 6.51 2.68 24.67 0.649 0.560
Female 5 8.35 9.17 4.79 4.62 4.96 2.68 24.67
Male 10 6.62 5.32 4.22 3.55 6.51 3.10 16.60
Change from 3 months to 1 Year
All 30 -0.76 2.75 -0.83 -2.49 1.66 -7.28 6.13 0.489 0.388
Female 10 -0.26 2.24 -0.57 -1.68 1.78 -4.28 2.62
Male 20 -1.01 2.99 -0.86 -2.81 0.27 -7.28 6.13
Change from baseline to 1 Year
All 15 5.15 6.07 6.86 2.68 9.49 -8.10 12.35 0.547 0.187
Female 5 3.75 5.35 5.31 2.69 6.02 -4.79 9.49
Male 10 5.85 6.55 7.27 6.50 9.91 -8.10 12.35
Change from baseline to 3 months
All 14 6.48 5.44 6.89 3.64 8.07 -4.31 16.66 0.226 0.096
Female 5 4.05 3.19 3.64 2.96 6.87 -0.51 7.29
Male 9 7.83 6.10 7.96 6.06 11.21 -4.31 16.66
First year height velocity (cm/yr)
All 32 12.97 4.60 11.91 9.93 14.59 6.46 26.86 0.941 0.656
Female 11 13.05 3.91 12.18 10.10 16.37 7.66 19.89
Male 21 12.93 5.02 11.51 9.93 13.63 6.46 26.86
Height velocity first 3 months of GH Rx
All 30 13.63 5.15 12.41 10.54 15.38 6.71 29.82 0.636 0.668
Female 10 12.98 4.82 12.22 9.56 15.38 7.92 24.16
Male 20 13.95 5.39 12.44 10.72 16.14 6.71 29.82
-
CT Registry ID#5123 Page 11
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 6. Summary of Height Velocity SDS
SUMMARY OF HEIGHT VELOCITY SDS -ANOVA p-values-
Group N Mean SD Median Q1 Q3 Min Max Raw Ranked
Baseline height velocity SDS
All 12 -1.38 2.64 -2.05 -2.57 -1.20 -3.75 6.56 0.701 0.523
Female 4 -1.82 1.30 -1.31 -2.59 -1.05 -3.75 -0.92
Male 8 -1.16 3.18 -2.07 -2.57 -1.62 -3.28 6.56
Change from baseline to 1 Year
All 12 6.58 5.03 7.93 3.52 9.12 -5.66 14.25 0.647 0.331
Female 4 5.58 2.99 5.00 3.13 8.03 3.10 9.22
Male 8 7.09 5.92 8.39 5.77 9.89 -5.66 14.25
First year height velocity SDS
All 31 4.51 2.92 5.04 2.10 6.12 -0.68 12.16 0.610 0.545
Female 11 4.14 3.17 2.53 2.10 5.50 -0.68 9.93
Male 20 4.71 2.83 5.26 2.76 6.24 -0.20 12.16
-
CT Registry ID#5123 Page 12
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 7. Summary of BMI (kg/m2)
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 31 16.1 2.4 15.8 14.4 17.5 11.7 21.7
Female 11 15.3 2.2 15.8 13.5 17.3 11.7 18.5
Male 20 16.5 2.5 15.8 14.5 17.6 12.8 21.7
After 1 Year
All 28 15.2 2.1 14.8 13.4 16.2 12.6 20.5
Female 9 14.5 1.7 14.0 13.2 15.3 12.6 17.6
Male 19 15.5 2.2 15.3 13.6 16.5 13.0 20.5
Change from Baseline to 1 Year
All 27 -0.6 1.2 -0.7 -1.5 0.3 -3.3 1.8 0.012 0.014
Female 9 -0.6 1.3 -0.5 -0.9 -0.1 -3.3 1.8 0.252 0.164
Male 18 -0.7 1.2 -0.9 -1.8 0.6 -2.5 1.1 0.029 0.038
Model Effects Baseline After 1 Year Change
ANOVA Comparison (Raw Data)
GENDER 0.190 0.259 0.792
ANOVA Comparison (Ranked Data)
GENDER 0.340 0.276 0.652
-
CT Registry ID#5123 Page 13
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 8. Summary of BMI SDS
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 26 -0.43 1.57 -0.26 -1.51 0.68 -4.86 1.92
Female 9 -1.08 1.94 -1.51 -1.60 0.46 -4.86 1.40
Male 17 -0.08 1.26 0.06 -0.91 0.68 -2.95 1.92
After 1 Year
All 23 -0.93 1.30 -0.38 -2.19 0.17 -3.06 1.31
Female 7 -1.30 1.38 -2.03 -2.56 -0.10 -2.62 0.80
Male 16 -0.77 1.28 -0.19 -1.87 0.18 -3.06 1.31
Change from Baseline to 1 Year
All 22 -0.30 1.06 -0.27 -0.91 0.18 -2.47 2.67 0.205 0.163
Female 7 0.07 1.23 0.03 -0.85 0.09 -1.02 2.67 0.880 0.938
Male 15 -0.47 0.97 -0.44 -1.23 0.28 -2.47 0.97 0.083 0.151
Model Effects Baseline After 1 Year Change
ANOVA Comparison (Raw Data)
GENDER 0.125 0.381 0.276
ANOVA Comparison (Ranked Data)
GENDER 0.212 0.398 0.708
-
CT Registry ID#5123 Page 14
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 9. Summary of Height
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 31 94.0 20.9 92.3 77.0 110.0 56.5 142.4
Female 11 90.3 19.5 87.8 70.5 103.2 64.5 129.4
Male 20 96.1 21.9 93.8 82.1 112.9 56.5 142.4
After 1 Year
All 28 103.4 19.1 102.5 87.2 116.6 74.5 151.7
Female 9 98.2 13.9 101.7 86.0 108.3 77.8 118.0
Male 19 105.8 21.1 103.0 88.4 122.6 74.5 151.7
Change from Baseline to 1 Year
All 27 11.6 3.5 10.7 9.3 13.3 6.2 22.0
-
CT Registry ID#5123 Page 15
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 10. Summary of Height SDS
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 26 -3.24 0.94 -3.12 -3.74 -2.74 -5.58 -1.21
Female 9 -3.76 1.04 -3.70 -4.36 -3.15 -5.58 -1.99
Male 17 -2.96 0.77 -3.01 -3.48 -2.36 -4.30 -1.21
After 1 Year
All 23 -2.20 0.98 -1.84 -3.22 -1.33 -3.68 -0.86
Female 7 -2.56 1.18 -2.98 -3.48 -0.94 -3.57 -0.86
Male 16 -2.04 0.87 -1.83 -2.77 -1.38 -3.68 -0.92
Change from Baseline to 1 Year
All 22 1.02 0.56 0.92 0.69 1.20 0.17 2.46
-
CT Registry ID#5123 Page 16
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 11. Summary of Weight (kg)
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 31 15.0 8.1 13.0 10.1 16.6 4.6 44.1
Female 11 12.7 5.2 12.5 9.0 14.4 5.8 25.3
Male 20 16.3 9.1 14.0 11.3 19.3 4.6 44.1
After 1 Year
All 28 17.1 8.5 15.5 11.8 18.8 7.6 45.4
Female 9 14.1 3.4 14.8 13.0 16.8 8.5 18.3
Male 19 18.6 9.9 16.0 11.0 23.4 7.6 45.4
Change from Baseline to 1 Year
All 27 2.9 1.4 2.9 2.0 3.8 0.5 6.5
-
CT Registry ID#5123 Page 17
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 12. Summary of Weight SDS
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 26 -2.9 2.0 -2.5 -3.8 -1.6 -9.7 0.2
Female 9 -4.0 2.4 -3.6 -4.3 -2.1 -9.7 -1.8
Male 17 -2.3 1.5 -2.1 -3.7 -1.3 -4.6 0.2
After 1 Year
All 23 -2.2 1.4 -2.3 -3.2 -0.8 -4.7 0.2
Female 7 -2.9 1.7 -3.2 -4.4 -0.8 -4.7 -0.2
Male 16 -1.9 1.2 -2.2 -2.8 -0.9 -4.1 0.2
Change from Baseline to 1 Year
All 22 0.9 1.2 0.8 -0.1 1.3 -0.7 5.0 0.002
-
CT Registry ID#5123 Page 18
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 13. Summary of IGF-I SDS
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 30 -2.67 2.37 -2.34 -3.62 -1.24 -7.88 0.67
Female 11 -2.23 2.48 -1.92 -2.60 0.25 -7.66 0.67
Male 19 -2.93 2.34 -2.86 -4.00 -1.24 -7.88 0.36
After 1 Year
All 28 -0.72 1.80 -0.91 -1.69 0.77 -4.04 2.51
Female 9 0.03 1.74 0.25 -1.16 0.87 -2.65 2.51
Male 19 -1.08 1.76 -1.25 -2.37 0.66 -4.04 2.40
Change from Baseline to 1 Year
All 26 2.25 2.09 2.22 1.02 3.35 -1.13 6.26
-
CT Registry ID#5123 Page 19
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 14. Summary of IGFB-3 SDS
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 25 -1.21 2.11 -0.57 -3.27 -0.14 -5.25 2.11
Female 9 -1.12 2.24 -0.57 -3.34 0.07 -4.47 1.90
Male 16 -1.26 2.10 -0.71 -2.91 -0.16 -5.25 2.11
After 1 Year
All 27 0.25 1.72 0.17 -0.74 1.81 -3.25 2.79
Female 9 0.27 1.88 0.17 -1.64 1.96 -1.95 2.79
Male 18 0.24 1.69 0.23 -0.72 1.63 -3.25 2.52
Change from Baseline to 1 Year
All 21 1.67 2.01 1.84 0.33 2.71 -1.72 6.27 0.001
-
CT Registry ID#5123 Page 20
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 15. Summary of IGF-I/IGFB-3 Ratio
Group N Mean SD Median Q1 Q3 Min Max t-test
p-value signed p-value
Baseline
All 25 31.90 18.10 26.99 21.94 39.53 4.39 78.69
Female 9 38.89 24.78 31.66 23.25 50.84 6.49 78.69
Male 16 27.96 12.27 26.66 20.31 36.72 4.39 48.48
After 1 Year
All 27 44.02 19.90 40.89 25.95 60.59 6.39 92.76
Female 9 50.77 16.95 51.89 36.32 64.98 25.95 74.21
Male 18 40.65 20.84 39.50 24.49 53.43 6.39 92.76
Change from Baseline to 1 Year
All 21 18.23 18.06 20.10 -0.82 26.92 -6.06 58.85
-
CT Registry ID#5123 Page 21
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 16. Summary of Serious Adverse Events on GH Treated
MedDRA SOC Term MedDRA Preferred Term
All Patients
Number of patients 32 Patients with >=1 SAE 5
(15.63%) Gastrointestinal disorders Any 1 (3.13%) Vomiting 1 (3.13%) Infections and infestations Any 2 (6.25%) Pharyngitis 1 (3.13%) Pneumonia 1 (3.13%) Injury, poisoning and procedural complications
Any 1 (3.13%)
Head injury 1 (3.13%) Metabolism and nutrition disorders Any 2 (6.25%) Hypoglycaemia 2 (6.25%)
Table 17. Summary of Treatment Emergent Adverse Events (TEAEs)
n % All 3
2 100.0
Patient has >=1 AE recorded (Y/N) N
11 34.4
Y 21 65.6
-
CT Registry ID#5123 Page 22
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 18. Summary of TEAEs by System Organ Class
MedDRA SOC Term MedDRA Preferred Term
All Patients
Blood and lymphatic system disorders Any 1 (3.13%) Anaemia 1 (3.13%) Eye disorders Any 1 (3.13%) Conjunctivitis 1 (3.13%) Gastrointestinal disorders Any 2 (6.25%) Diarrhoea 1 (3.13%) Vomiting 1 (3.13%) General disorders and administration site conditions
Any 2 (6.25%)
Pyrexia 2 (6.25%) Infections and infestations Any 16
(50.00%) Bronchitis 5 (15.63%) Bronchopneumonia 1 (3.13%) Ear infection 3 (9.38%) Gastroenteritis 3 (9.38%) Influenza 2 (6.25%) Nasopharyngitis 1 (3.13%) Pharyngitis 2 (6.25%) Pneumonia 1 (3.13%) Tonsillitis 1 (3.13%) Varicella 5 (15.63%) Wound infection 1 (3.13%) Injury, poisoning and procedural complications Any 2 (6.25%) Head injury 1 (3.13%) Multiple fractures 1 (3.13%) Metabolism and nutrition disorders Any 3 (9.38%) Hypoglycaemia 2 (6.25%) Iron deficiency 1 (3.13%) Nervous system disorders Any 1 (3.13%) Dizziness 1 (3.13%) Psychiatric disorders Any 1 (3.13%) Vomiting psychogenic 1 (3.13%) Respiratory, thoracic and mediastinal disorders Any 1 (3.13%) Cough 1 (3.13%)
(continued)
-
CT Registry ID#5123 Page 23
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 18. Summary of TEAEs by System Organ Class (concluded)
MedDRA SOC Term MedDRA Preferred Term
All Patients
Skin and subcutaneous tissue disorders Any 2 (6.25%) Skin lesion 1 (3.13%) Urticaria 1 (3.13%)
Table 19. Summary of Drug Related Treatment-Emergent Specific Medical Conditions (SMC)
All Patients
Number of patients 32
Patients with >=1drug related SMC (Intestinal disturbances)
2 ( 6.25%)
Table 20. Summary of Treatment-Emergent Specific Medical Conditions (SMC)
All Patients
Number of patients 32 Patients with >=1 SMC (Recurrent otitis media)
1 (3.13%)
-
CT Registry ID#5123 Page 24
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
Table 21. Frequencies of TEAE and SMC in Patients by GH Dose Group
GH doses are starting doses (mg/Kg/wk)
All < 0.15 0.15 - < 0.30 0.30 - < 0.45
n % n % n % n % Patient has >=1 AE recorded (Y/N) N
11
34.4 0 0 4 44.4 7 31.8
Y 21
65.6 1
100.0 5 55.6 15 68.2
Patients with >=1 SMC N
31
96.9 1
100.0 8 88.9 22 100.0
Y 1 3.1 0 0 1 11.1 0 0 Patients with >=1 SMC drug related N
30
93.8 1
100.0 9 100.0 20 90.9
Y 2 6.3 0 0 0 0 2 9.1
Table 22. Comparison of TEAEs between GH dosage groups
GH doses are starting doses (mg/Kg/wk) < 0.15 0.15 - < 0.30 0.30 - < 0.45 All Patient has >=1 AE recorded (Y/N) n % n % n % n % Yes 1 100.
0 5 55.6 15 68.2 21 65.6
All 1 100.0
9 100.0 22 100.0 32 100.0
No 4 44.4 7 31.8 11 34.4
-
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
CT Registry ID#5123 Page 25
Table 23. Listing of Serious Adverse Events (SAE)
Patient group Therapy Diagnosis
Age (y) at GH Start, Gender,
History of neoplasia
Age at SAE, Years since
GH Rx start, Years since
GeNeSIS entry to SAE onset
Actual term, MedDRA SOC,
MedDRA Preferred Term
SAE duration Severity, Causal,
Relationship
Seriousness, Criteria,
Discontinuation
due to AE Naive
GH treated Pituitary hypoplasia
MINOR HEAD TRAUMA Injury, poisoning and procedural
complications Head injury
1 Day Severe
Not related
Yes Hospitalization
No
Naive GH treated
Pituitary aplasia
VOMITING Gastrointestinal disorders
Vomiting
1 Day Moderate
Not related
Yes Hospitalization
No Naive
GH treated Pituitary aplasia
HYPOGLYCEMIA Metabolism and nutrition disorders
Hypoglycaemia
1 Day Moderate
Not related
Yes Hospitalization
No Naive
GH treated Classic
ACUTE PHARYNGITIS Infections and infestations
Pharyngitis
7 Days Mild
Not related
Yes Hospitalization
No Naive
GH treated Ectopic posterior
pitui
PNEUMONIA Infections and infestations
Pneumonia
10 Days Severe
Not related
Yes Hospitalization
No
Naive GH treated
Classic
KETOTIC HYPOGLYCAEMIA Metabolism and nutrition disorders
Hypoglycaemia
3 Days Moderate Related
Yes Hospitalization
No
-
CT Registry ID#5123 Page 26
Humatrope Copyright © 2006 Eli Lilly and Company. All rights reserved.
References
(1) Tanner JM, Whitehouse RH, 1976. Archives of Disease in childhood, Vol 51, p 170.